CEL-SCI Co. (NYSEAMERICAN:CVM) saw a large decline in short interest in the month of December. As of December 29th, there was short interest totalling 510,101 shares, a decline of 3.2% from the December 15th total of 526,760 shares. Approximately 4.6% of the shares of the company are sold short. Based on an average daily volume of 161,531 shares, the short-interest ratio is currently 3.2 days.

Separately, Dawson James reissued a “neutral” rating on shares of CEL-SCI in a research note on Monday, October 16th.

Shares of CEL-SCI (CVM) opened at $1.99 on Thursday. CEL-SCI has a 52 week low of $1.46 and a 52 week high of $4.50. The stock has a market capitalization of $23.07, a P/E ratio of -1.23 and a beta of -1.60.

In other CEL-SCI news, Director Vicente Benjamin Asuncion sold 160,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 17th. The stock was sold at an average price of $0.39, for a total transaction of $62,400.00.

ILLEGAL ACTIVITY WARNING: This piece of content was first published by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright laws. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2018/01/11/cel-sci-co-cvm-sees-significant-decrease-in-short-interest.html.

CEL-SCI Company Profile

CEL-SCI Corporation is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company is focused on activating the immune system to fight cancer and infectious diseases. It operates through the segment of research and development of certain drugs and vaccines.

Receive News & Ratings for CEL-SCI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CEL-SCI and related companies with MarketBeat.com's FREE daily email newsletter.